Tags

Type your tag names separated by a space and hit enter

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.
Intern Med J 2015; 45(11):1154-60IM

Abstract

BACKGROUND

Musculoskeletal symptoms are the most common extra-intestinal manifestation associated with inflammatory bowel disease (IBD). Spondyloarthritis (SpA) is an umbrella term applied to a group of rheumatic diseases with some features in common and others distinct from other inflammatory arthritides.

AIM

To determine self-reported prevalence of SpA associated musculoskeletal manifestations in an IBD cohort on tumour necrosis factor (TNF) inhibitors using a questionnaire incorporating Assessment of SpondyloArthritis International Society (ASAS) criteria.

METHODS

Consecutive IBD patients on TNF inhibitors attending a single IBD centre (May-September 2011) were asked to complete a SpA questionnaire. Data collected included SpA and IBD variables, demographics, concurrent medications, co-morbidities and autoimmune serology.

RESULTS

The 140-patient cohort included 96 suffering from Crohn disease and 44 from ulcerative colitis. The mean age of disease onset was 29.3 years and 45% were men. Concurrent or past history of inflammatory back pain was reported by 29% subjects. Using the imaging and clinical arms of the ASAS criteria, 30% and 14% subjects respectively had axial SpA. Arthritis was reported by 34%, enthesitis 17%, dactylitis 4%, uveitis 6%, psoriasis 6% and a family history of SpA in 39%. Peripheral SpA was present in 41% by the ASAS criteria. There were no differences in these frequencies between Crohn disease and ulcerative colitis. A positive antinuclear antibodies (>1:80) was found in 19% before commencement of TNF inhibitor therapy and increased to 78% on therapy. Clinical drug-induced lupus erythematosus was uncommon (4%) and was characterised by new clinical signs and symptoms, including arthralgia, rash with elevated dsDNA titres and positive antinuclear antibodies.

CONCLUSIONS

Inflammatory bowel disease patients on TNF inhibitors frequently reported musculoskeletal manifestations. Increased recognition of SpA occurred with use of an SpA self-reported questionnaire in IBD patients: this could alter management and improve patient outcomes. Clinical drug-induced lupus erythematosus was uncommon.

Authors+Show Affiliations

Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia. Australian National University Medical School, Canberra, Australian Capital Territory, Australia.Rheumatology Department, Canberra Hospital, Canberra, Australian Capital Territory, Australia. Australian National University Medical School, Canberra, Australian Capital Territory, Australia.Centre for Advances in Epidemiology and Information Technology, Canberra Hospital, Canberra, Australian Capital Territory, Australia. Australian National University Medical School, Canberra, Australian Capital Territory, Australia.Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia. Australian National University Medical School, Canberra, Australian Capital Territory, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26337851

Citation

Subramaniam, K, et al. "Spondyloarthropathy in Inflammatory Bowel Disease Patients On TNF Inhibitors." Internal Medicine Journal, vol. 45, no. 11, 2015, pp. 1154-60.
Subramaniam K, Tymms K, Shadbolt B, et al. Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors. Intern Med J. 2015;45(11):1154-60.
Subramaniam, K., Tymms, K., Shadbolt, B., & Pavli, P. (2015). Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors. Internal Medicine Journal, 45(11), pp. 1154-60. doi:10.1111/imj.12891.
Subramaniam K, et al. Spondyloarthropathy in Inflammatory Bowel Disease Patients On TNF Inhibitors. Intern Med J. 2015;45(11):1154-60. PubMed PMID: 26337851.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors. AU - Subramaniam,K, AU - Tymms,K, AU - Shadbolt,B, AU - Pavli,P, PY - 2015/03/23/received PY - 2015/08/16/accepted PY - 2015/9/5/entrez PY - 2015/9/5/pubmed PY - 2016/9/13/medline KW - clinical drug-induced lupus erythematosus KW - inflammatory bowel disease KW - spondyloarthritis KW - tumour necrosis factor inhibitors SP - 1154 EP - 60 JF - Internal medicine journal JO - Intern Med J VL - 45 IS - 11 N2 - BACKGROUND: Musculoskeletal symptoms are the most common extra-intestinal manifestation associated with inflammatory bowel disease (IBD). Spondyloarthritis (SpA) is an umbrella term applied to a group of rheumatic diseases with some features in common and others distinct from other inflammatory arthritides. AIM: To determine self-reported prevalence of SpA associated musculoskeletal manifestations in an IBD cohort on tumour necrosis factor (TNF) inhibitors using a questionnaire incorporating Assessment of SpondyloArthritis International Society (ASAS) criteria. METHODS: Consecutive IBD patients on TNF inhibitors attending a single IBD centre (May-September 2011) were asked to complete a SpA questionnaire. Data collected included SpA and IBD variables, demographics, concurrent medications, co-morbidities and autoimmune serology. RESULTS: The 140-patient cohort included 96 suffering from Crohn disease and 44 from ulcerative colitis. The mean age of disease onset was 29.3 years and 45% were men. Concurrent or past history of inflammatory back pain was reported by 29% subjects. Using the imaging and clinical arms of the ASAS criteria, 30% and 14% subjects respectively had axial SpA. Arthritis was reported by 34%, enthesitis 17%, dactylitis 4%, uveitis 6%, psoriasis 6% and a family history of SpA in 39%. Peripheral SpA was present in 41% by the ASAS criteria. There were no differences in these frequencies between Crohn disease and ulcerative colitis. A positive antinuclear antibodies (>1:80) was found in 19% before commencement of TNF inhibitor therapy and increased to 78% on therapy. Clinical drug-induced lupus erythematosus was uncommon (4%) and was characterised by new clinical signs and symptoms, including arthralgia, rash with elevated dsDNA titres and positive antinuclear antibodies. CONCLUSIONS: Inflammatory bowel disease patients on TNF inhibitors frequently reported musculoskeletal manifestations. Increased recognition of SpA occurred with use of an SpA self-reported questionnaire in IBD patients: this could alter management and improve patient outcomes. Clinical drug-induced lupus erythematosus was uncommon. SN - 1445-5994 UR - https://www.unboundmedicine.com/medline/citation/26337851/Spondyloarthropathy_in_inflammatory_bowel_disease_patients_on_TNF_inhibitors_ L2 - https://doi.org/10.1111/imj.12891 DB - PRIME DP - Unbound Medicine ER -